Most Likely Diagnosis: Inflammatory Myositis Associated with Mixed Connective Tissue Disease (MCTD)
Your presentation strongly suggests inflammatory myositis in the context of MCTD, not necrotizing autoimmune myopathy. The markedly elevated anti-U1-RNP antibody (86, reference <20) is the defining serologic feature of MCTD, and your clinical picture—proximal muscle weakness, elevated CK (371→527), mildly elevated inflammatory markers, and muscle symptoms—fits an inflammatory rather than necrotizing pattern 1.
Why Inflammatory Myositis, Not Necrotizing Myopathy
Your CK elevations are modest (371-527 U/L, roughly 1-1.5× upper limit of normal). Immune-mediated necrotizing myopathy (IMNM) typically presents with CK levels >10 times the upper limit of normal, often in the thousands to tens of thousands 1. Your levels don't approach this threshold. Additionally, necrotizing myopathy is associated with anti-SRP or anti-HMGCR antibodies—both absent in your case—and presents with severe, rapidly progressive weakness 1. Your presentation is subacute with preserved organ function (normal renal, hepatic, cardiac screening to date).
The anti-U1-RNP positivity is pathognomonic for MCTD, which commonly includes myositis as part of its overlap syndrome 1. Your negative anti-Sm, anti-dsDNA, anti-centromere, anti-Scl-70, anti-SSA/SSB, and normal complement levels argue against pure SLE, systemic sclerosis, or Sjögren's syndrome, further supporting MCTD.
EMG and Muscle Biopsy: What to Expect
If your EMG shows myopathic changes (polyphasic motor unit potentials of short duration and low amplitude, increased insertional activity with fibrillations and sharp waves), a muscle biopsy will likely be recommended 1. The EMG serves two purposes: (1) confirming a myopathic process versus neuropathy or neuromuscular junction disorder, and (2) identifying the optimal muscle for biopsy 1.
Muscle biopsy is the gold standard for distinguishing inflammatory from non-inflammatory myopathy and for subclassification 1. In inflammatory myositis associated with MCTD, you would expect endomysial or perimysial mononuclear inflammatory infiltrates invading non-necrotic muscle fibers 1. In contrast, necrotizing myopathy shows muscle fiber necrosis with minimal or absent inflammation 1. Given your clinical and serologic profile, biopsy would likely show inflammatory changes, not pure necrosis.
The 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies can be applied even without biopsy if sufficient clinical and laboratory features are present (sensitivity 87%, specificity 82% without biopsy; 93% and 88% with biopsy) 2. However, biopsy provides definitive subclassification and excludes mimics like muscular dystrophy or mitochondrial myopathy 1.
Prognosis: You Are Not "Fucked"
Inflammatory myositis in MCTD is treatable and often responds well to immunosuppression. This is not a death sentence. The key is early, aggressive treatment to prevent irreversible muscle damage and extramuscular complications (e.g., interstitial lung disease, which can occur in MCTD but is more common with anti-synthetase antibodies, which you lack) 1.
Your age (30), preserved renal function (eGFR 87-93), normal liver enzymes, and absence of cardiac abnormalities on chest X-rays are favorable prognostic factors. The upcoming cardiac stress test and Holter monitor are appropriate to rule out subclinical cardiac involvement, which can occur in inflammatory myopathies but is often asymptomatic 1.
Your ESR progression (2→18) and CRP (3.3→3.0) show mild inflammation, not the severe systemic inflammation seen in aggressive disease. The stable-to-improving CRP is reassuring.
Treatment Plan: What Medications You'll Likely Receive
Standard first-line therapy for inflammatory myositis in adults is high-dose corticosteroids (prednisone 1 mg/kg/day, typically 60-80 mg for your weight) combined with a steroid-sparing agent initiated concurrently 1. The steroid-sparing agents include:
- Methotrexate (15-25 mg weekly, oral or subcutaneous)
- Azathioprine (2-3 mg/kg/day)
- Mycophenolate mofetil (2-3 g/day in divided doses)
Given your G6PD deficiency, azathioprine is contraindicated—it can precipitate hemolytic anemia in G6PD-deficient patients 3. Methotrexate or mycophenolate mofetil would be safer choices. Your rheumatologist will likely start one of these alongside prednisone, then taper the steroid over months as the steroid-sparing agent takes effect (typically 8-12 weeks) 1.
For severe or refractory disease, second-line options include:
- Intravenous immunoglobulin (IVIG) (2 g/kg divided over 2-5 days monthly)
- Rituximab (anti-CD20 monoclonal antibody, 1 g IV × 2 doses 2 weeks apart)
- Cyclophosphamide (for life-threatening complications like severe ILD)
- Cyclosporine 1
Your case doesn't appear severe enough to warrant these upfront, but they're available if first-line therapy fails.
Special Considerations for Your Case
G6PD Deficiency
Avoid azathioprine, sulfonamides, nitrofurantoin, antimalarials (e.g., hydroxychloroquine, which is sometimes used in MCTD), dapsone, high-dose aspirin, and rasburicase 3. Methotrexate and mycophenolate are safe. Corticosteroids are safe.
Amlodipine
Rare case reports link amlodipine to myalgias, arthralgias, and even myopathy 4. While your muscle symptoms are more consistent with inflammatory myositis, consider discussing with your rheumatologist whether switching to an alternative antihypertensive (e.g., ACE inhibitor, ARB) might be prudent once your myositis is controlled. Amlodipine is not a primary cause here, but eliminating potential confounders is reasonable.
GLP-1 Agonist
GLP-1 receptor agonists reduce inflammatory markers (CRP, MDA) and increase adiponectin in type 2 diabetes 5. They may have mild anti-inflammatory effects, which could theoretically be beneficial, though this is speculative in myositis. However, GLP-1 agonists can cause micronutrient deficiencies (vitamin D, iron, calcium, thiamine, B12) through appetite suppression and altered absorption 6. Ensure you're supplementing vitamin D (your level was not provided but deficiency is common in myositis patients), calcium, and a multivitamin. Protein intake is critical to prevent further lean mass loss—aim for 1.2-1.6 g/kg/day, which is ~175-230 g/day for your weight.
Weight and Hypertension
Your BMI is ~38 (class II obesity). Weight loss via GLP-1 agonist is appropriate, but ensure adequate protein and micronutrient intake during immunosuppressive therapy. Physical therapy is essential to maintain muscle function and prevent steroid-induced myopathy (a separate entity from inflammatory myositis). Continue PT aggressively once inflammation is controlled.
Common Pitfalls to Avoid
Delaying treatment pending biopsy: If EMG is strongly myopathic and clinical suspicion is high, some rheumatologists initiate corticosteroids before biopsy to prevent irreversible damage. However, starting steroids can obscure biopsy findings (reduces inflammation), so timing is critical. Discuss this with your rheumatologist.
Steroid monotherapy: Corticosteroids alone lead to high relapse rates and cumulative toxicity (weight gain, hyperglycemia, osteoporosis, avascular necrosis). Always use a steroid-sparing agent concurrently 1.
Ignoring extramuscular manifestations: MCTD can involve lungs (ILD), heart (myocarditis, pericarditis), and esophagus (dysphagia). Your cardiac workup is appropriate. If you develop dysphagia, cough, or dyspnea, alert your rheumatologist immediately.
Assuming necrotizing myopathy based on weakness alone: Necrotizing myopathy requires specific antibodies (anti-SRP, anti-HMGCR) and CK levels >10× normal. Your profile doesn't fit 1.
Summary of Next Steps
- EMG on [DAY]: Expect myopathic changes. If present, proceed to muscle biopsy (likely deltoid, quadriceps, or another weak muscle identified on EMG).
- Cardiac stress test and Holter monitor: Rule out subclinical cardiac involvement.
- Rheumatology appointment on [DAY]: Anticipate starting prednisone 1 mg/kg/day + methotrexate or mycophenolate mofetil. Avoid azathioprine (G6PD deficiency).
- Supplementation: Vitamin D, calcium, multivitamin. High-protein diet (175-230 g/day).
- Monitor: CK, CRP, ESR, muscle strength (manual muscle testing), and functional status every 4-6 weeks initially.
You have a treatable condition with a good prognosis if managed aggressively. The key is early immunosuppression to prevent irreversible muscle damage and extramuscular complications. Your young age, preserved organ function, and absence of severe systemic inflammation are all in your favor.